We therefore performed a prospective directly comparative study to investigate the detection rate of [18F]PSMA-1007 and [18F]Fluciclovine in patients with early BCR of prostate cancer, with low PSA levels, i.e. 0.2–5.0 μg/L. The gene discussed is BCR; the disease is prostate cancer.